Lehrstuhl für Haut- und Geschlechtskrankheiten

Characterization and Manipulation of the Crosstalk Between Dendritic and Natural Killer Cells Within the Tumor Microenvironment (2021) Jacobs B, Gebel V, Heger L, Greze V, Schild H, Dudziak D, Ullrich E Journal article, Review article Factors influencing the adjuvant therapy decision: Results of a real-world multicenter data analysis of 904 melanoma patients (2021) Lodde G, Forschner A, Hassel J, Wulfken LM, Meier F, Mohr P, Kähler K, et al. Journal article NanoString technology distinguishes anti-TIF-1γ+ from anti-Mi-2+ dermatomyositis patients (2021) Preusse C, Eede P, Heinzerling L, Freitag K, Koll R, Froehlich W, Schneider U, et al. Journal article Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group (2021) Grimmelmann I, Momma M, Zimmer L, Hassel JC, Heinzerling L, Pföhler C, Loquai C, et al. Journal article Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition (2021) Knispel S, Gassenmaier M, Menzies AM, Loquai C, Johnson DB, Franklin C, Gutzmer R, et al. Journal article Select hyperactivating NLRP3 ligands enhance the TH1-and TH17-inducing potential of human type 2 conventional dendritic cells (2021) Hatscher L, Lehmann C, Purbojo A, Onderka C, Liang C, Hartmann A, Cesnjevar R, et al. Journal article, Original article The Road to Effective Cancer Immunotherapy—A Computational Perspective on Tumor Epitopes in Anti-Cancer Immunotherapy (2021) Lischer C, Vera González J Book chapter / Article in edited volumes Online-Konsensuskonferenzen für die Entwicklung und Aktualisierung von Leitlinien für die klinische Praxis: Eine Umfrage unter den Teilnehmenden der deutschen S3-Leitlinie zur aktinischen Keratose und kutanem Plattenepithelkarzinom (2021) Steeb T, Follmann M, Langer T, Nothacker M, Wessely A, Garbe C, Leiter U, et al. Journal article Hematological immune related adverse events after treatment with immune checkpoint inhibitors (2021) Kramer R, Zaremba A, Moreira A, Ugurel S, Johnson DB, Hassel JC, Salzmann M, et al. Journal article Development of combination therapy to delay resistance in BRAF-inhibitor treated melanoma (2021) Seretis A, Cappellano G, Bellmann L, Hornsteiner F, Tripp CH, Ortner-Tobider D, Mullins DW, et al. Conference contribution